Abstract. The present study showed that the combination of dasatinib and combretastatin A-4 (CA-4) exhibited synergistic cytotoxicity in multiple types of cancer, including ovarian, hepatocellular, lung and prostate carcinoma. The enhanced apoptosis induced by dasatinib plus CA-4 was accompanied by a greater extent of mitochondrial depolarization, caspase-3 activation and PARP cleavage in HO-8910 cells. Furthermore, elevated expression of Mcl-1 led to a reduced apoptosis induced by dasatinib plus CA-4, highlighting that downregulated Mcl-1 was necessary for the potentiating effect of dasatinib to CA-4-triggered apoptosis. A clear increase in γ-H2AX expression was observed in the dasatinib + CA-4 group compared with the mono-treatment groups, indicating that dasatinib plus CA-4 may induce double-strand breaks (DSBs) in HO-8910 cells. Moreover, the increased anticancer efficacy of dasatinib combined with CA-4 was further validated in a human HO-8910 ovarian cancer xenograft model in nude mice. Our study is the first to show that the combination of dasatinib with CA-4 could be a novel and promising therapeutic approach for the treatment of cancer.
Introduction
Combretastatin A-4 (CA-4), a natural product isolated from the bark of a south african tree combretum caffrum, is a highly effective antiangiogenic agent that causes vascular shutdown, leading to tumor death (1) . CA-4 phosphate (CA-4P), a water soluble pro-drug of CA-4, is rapidly dephosphorylated to the active compound CA-4 and shows reversible binding kinetics to tubulin, leading to disruption of microtubular structures (2, 3) . Although CA-4P is being studied in clinical trials as a vascular disrupting agent, cardiovascular toxicity and neurotoxicity are dose limiting for CA-4P (4, 5) . These severe side-effects currently represent the main obstacles to broad clinical application of CA-4P (2) . Thus, it is important to develop new antitumor combination therapy with lower concentrations of CA-4 and more specificity for tumor endothelial cells than normal endothelial cells to avoid cardiac toxicity from endothelial damage.
Tyrosine kinase inhibitors (TKIs) are rapidly being integrated into the management of a variety of malignant diseases (6) . Dasatinib, a novel orally bioactive TKI currently used to treat patients with hematologic and solid malignancies, correlated with a combined targeting of PDGFR-β and VEGFR/c-Src signaling pathways (7) (8) (9) . The Src kinases have multiple substrates that lead to diverse biological effects in cancer cells, including changes in proliferation, motility, invasion, survival and angiogenesis (10) . Dasatinib suppresses tumor angiogenesis, invasion, and metastasis by inhibiting Src expression (11) . Cardiovascular and hematologic toxicity are dose limiting for dasatinib; thus, it is necessary to develop new anticancer combination therapy with lower concentrations of dasatinib to avoid these major side-effects (12) . Dasatinib has shown synergistic anticancer activity in combination with chemotherapeutic agents including paclitaxel, ixabepilone and erlotinib (12) (13) (14) .
The tumor vasculature is critical to both the survival of a solid tumor mass and its continued growth (15) . Angiogenesis is a complex process that occurs in a variety of physiologic and pathophysiologic states and is a remodeling of an established primitive network of blood vessels. Angiogenesis is a complex process that is essential for growth, invasion and metastasis of tumors (16) . Vascular targeting agents (VTAs) comprise a novel class of anticancer agents which can be divided into two groups; those that inhibit angiogenesis (angiogenesis inhibitors) and those that target established vessels (vascular disrupting agents) (17) . Various combinations involving an antiangiogenic agent and an antivascular agent have shown considerable promise in preclinical models and such combinations are currently beginning to be evaluated in patients (18, 19) . Thus, we hypothesized that combining the antiangiogenic drug dasatinib with the antivascular agent CA-4 might potentially enhance the anticancer therapeutic effects. In the present study, we showed for the first time that dasatinib and CA-4 in combination had substantial synergistic antitumor efficacy against human cancer cells in vitro and in vivo. In addition, dasatinib greatly enhanced CA-4-mediated apoptosis in HO-8910 cells, accompanied by increased extent of mitochondrial depolarization, cleavage of PARP and activation of caspase cascades. Notably, our results demonstrated that dasatinib plus CA-4 leads to increased levels of γ-H2AX indicating increased DNA damage in HO-8910 cells. These data suggested that the combination of dasatinib and CA-4 might be an effective therapeutic strategy to achieve synergistic activities in patients with solid tumors. Chemical structures of the agents are shown in Fig. 1A .
Enhanced antitumor activity by the combination of dasatinib and combretastatin A-4 in vitro and in vivo

Materials and methods
Materials. CA-4 was synthesized at the Department of Chemical and Biochemical Engineering, Zhejiang University. Dasatinib was supplied by LC Laboratories (Woburn, MA, USA). The primary antibodies against Mcl-1 (S-19), Bax (Δ21), Bcl-2 (C-2), PARP (H250), pro-caspase-3 (H-277), XIAP (A-7), γ-H2AX (Ser139), and HRP-labeled secondary antimouse and anti-rabbit antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA); cytochrome c (136F3), cleaved-caspase-3 (D-175) were purchased from Cell Signaling Technology (Danvers, MA, USA); β-actin was purchased from BD Biosciences (Franklin Lakes, NJ, USA).
Cell culture. Human ovarian cancer cell line (HO-8910), human hepatocellular carcinoma cell line (HepG2, SMMC-7721), human non-small cell lung cancer cell line (A549) and human prostate cancer cell line (PC-3) were purchased from the Shanghai Institute of Biochemistry and Cell Biology (Shanghai, China); they were tested and authenticated for genotypes by DNA fingerprinting. HO-8910 and HepG2 were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS). A549 and PC-3 were grown in Ham's F12 medium supplemented with 10% FBS, and SMMC-7721 was cultured in RPMI-1640 medium supplemented with 10% FBS. All the cells were maintained in a humidified atmosphere of 95% air plus 5% CO 2 at 37˚C.
Cytotoxicity assay. The antiproliferative activity of combination treatment with dasatinib and CA-4 was measured by sulforhodamine blue (SRB) cytotoxicity assay. Briefly, cells were fixed with 10% TCA solution for 1 h, wells were rinsed 5 times with tap water and then cells were stained with 0.4% SRB solution (100 µl/well) for at least 20 min at room temperature. Wells were rinsed with 1% acetic acid to remove unbound dye and were then left to air dry. The SRB dye was then solubilized by placing 100 µl of unbuffered Tris-based solution in each well, and the absorbance was measured at 515 nm using a multi-scan spectrum. The inhibition rate of cell proliferation was calculated for each well as (A515 control cells -A515 treated cells)/A515 control cells x 100%.
Analysis of apoptosis by propidium iodide (PI) staining.
Cells (4x10 5 /well) were seeded into 6-well plates and exposed to dasatinib, CA-4 or the combination for 48 h. Cells were harvested and washed with PBS, fixed with pre-cooled 70% ethanol at 4˚C overnight. Fixed cells were then washed with PBS to remove residual ethanol, pelleted, resuspended in 500 µl PBS containing 50 µg RNase A at 37˚C and 5 µg PI in the dark at room temperature for 30 min. For each sample, 2x10 4 cells were collected and analyzed using an FACSCalibur cytometer (Becton-Dickinson, San Jose, CA, USA).
Analysis of apoptosis by DAPI staining. Briefly, cells in 96-well plates treated with dasatinib, CA-4 or the combination were washed twice with PBS, and then incubated with 0.1% Triton and 0.1% DAPI. The morphology of the cell nuclei was observed and captured using a fluorescence microscope at excitation wavelength 350 nm.
Determination of mitochondrial membrane depolarization.
Cells (4x10 5 /well) were exposed to dasatinib, CA-4 or the combination for 48 h. They were then collected and resuspended in fresh medium containing 10 µg/ml 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazol-carbocyanine iodide (JC-1). Following incubation at 37˚C for 30 min, cells were analyzed by flow cytometry (20) .
Cell lysates and western blot analysis. Proteins were extracted with lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 0.5% deoxycholic acid, 0.02% sodium azide, 1% NP-40, 2.0 µg/ml aprotinin, 1 mM phenylmethylsulfonylfluoride). The lysates were centrifuged at 10,000 x g for 30 min at 4˚C. The supernatants were transferred to a new tube and the protein concentration was determined. To analyze cytochrome c release from mitochondria, mitochondria was extracted using Mitochondria/Cytosol Fractionation kit (Beyotime Institute of Biotechnology, Haimen, China). Proteins were fractionated on 8-15% Tris-glycine gels, and they were then transferred to PVDF membranes (Millipore, Bedford, MA, USA) and probed with primary antibodies (dilution range 1:500-1:1,000) followed by horseradish peroxidase-labeled secondary antibodies at 1:5,000 dilution. Antibody binding was then detected with the use of a chemiluminescent substrate and visualized on autoradiography film (21) .
Immunofluorescence. Cells were seeded onto 35-mm dishes and exposed to dasatinib, CA-4 or the combination for 48 h. Subsequently, the cells were fixed with 4% formaldehyde for 15 min. After washing with PBS, the cells were blocked with 10% serum in PBS for 10 min and incubated at 37˚C for 2 h with γ-H2AX (1:200; Santa Cruz Biotechnology). The cells were then washed and incubated in the dark for 1 h at 37˚C with goat anti-rabbit (FITC)-conjugated antibodies (1:200; Earthbox, San Francisco, CA, USA). After washing, the nuclei were counterstained with DAPI and the cells were then washed in PBS and examined using a laser-scanning confocal microscopy (FluoView, Olympus, Tokyo). 
Animals and antitumor activity in vivo.
Human ovarian cancer HO-8910 xenografts were established by injecting 5x10 6 cells subcutaneously into nude mice. When the tumor reached a volume of 50-150 mm 3 , the mice were randomized to control and treated groups, and received vehicle (0.9% sodium chloride, i.v. administration), CA-4 (6 mg/kg, 1% DMSO, 7% cremophor/ethanol (3:1), and 92% sodium chloride, i.p. administration), dasatinib (5 mg/kg, i.g. administration) 4 times per week for 19 days. Mouse weight and tumor volume were measured individually twice per week with microcalipers until animals were sacrificed. Tumor volume (V) was calculated as V = (length x width x high)/2. The tumor volume at day n was expressed as RTV according to the following formula: RTV = TVn/TV0, where TVn is the tumor volume at day n and TV0 is the tumor volume at day 0. Therapeutic effects of treatment were expressed in terms of T/C % using the calculation formula T/C (%) = mean RTV of the treated group/mean RTV of the control group x 100%.
Statistical analyses. Two tailed Student's t-tests were used to determine the significance of differences between the experiment conditions. Differences were considered statistically significant at P<0.05. Combination index (18) was well-accepted for quantifying drug synergism based on the multiple drug-effect equation of Chou-Talalay (23, 24) . For in vitro experiments, CI values were calculated for each concentration of dasatinib, CA-4 and the combination in cell proliferation assays using Calcusyn (Biosoft, Cambridge, UK). Different CI values were obtained when solving the equation for different effect levels, and mean CI values were chosen for presentation. A CI<0.9 indicated synergism; 0.1, very strong synergism; 0.1-0.3, strong synergism; 0.3-0.7, synergism; 0.7-0.85, moderate synergism; 0.85-0.9, slight synergism; 0.9-1.10, additive; and >1.10, antagonism.
Results
Cytotoxicity of the dasatinib and CA-4 combination in human
cancer cell lines. Firstly, the cytotoxicity was determined using SRB assay, after a 72-h exposure to dasatinib, CA-4 and the combination at the indicated concentration in 5 human cancer cell lines. Survival curves to dasatinib, CA-4, and dasatinib combined with CA-4 are shown in Fig. 1B . CI values were calculated using Calcusyn at the fixed-ratio concentrations of dasatinib and CA-4 to assess combination activity. Dasatinib plus CA-4 showed synergy in HO-8910, A549, SMMC-7721, HepG2 and PC-3 cell lines, with the mean CI values <0.7 (Fig. 1B) .
Dasatinib synergizes with CA-4 to trigger apoptosis. To explore the mechanism of synergistic effects by combining dasatinib and CA-4, we first detected apoptosis by PI staining in HO-8910 and A549 cells that showed strong synergistic effects in the cytotoxicity assay. As shown in Fig (Fig. 2D and E) . Furthermore, DAPI staining was also performed to visualize the apoptosis by assessing chromatin condensation. As shown in Fig. 3A , 10 µM dasatinib plus 200 nM CA-4 triggered more apoptosis than the mono-treatment in HO-8910 cells, as indicated by the apoptotic bodies.
Dasatinib plus CA-4 combination therapy causes mitochondrial release of proapoptotic molecules for activation of proteases leading to substrate cleavage. Since caspase-3/PARP play a key role in the initiation of cellular events during the apoptotic process, we next examined the effect of dasatinib, CA-4, and the combination on the activation of caspase-3, cleavage of PARP. As shown in Fig. 3B , we found that although dasatinib and CA-4 had slight effect on caspase-3 and PARP, the two together were highly effective, inducing more signifi-cant cleavage of PARP and caspase-3. The X-linked inhibitor of apoptosis (XIAP) is the most potent caspase inhibitor in the IAP family and inhibits apoptotic cell death predominantly by preventing activation of initiator caspase-9 as well as effectors caspases-3 and -7 (25) . Treatment of the cells with dasatinib plus CA-4 caused a significantly greater reduction of XIAP than either agent used alone. Moreover, dasatinib plus CA-4 combination treatment resulted in the decrease of Bcl-2 and increase of Bax, with an increase in the Bax/Bcl-2 ratio (Fig. 3B) . To further confirm the combination effect of dasatinib and CA-4 on the induction of the mitochondrial apoptosis pathway, we also examined cytochrome c release from mitochondria to cytosol. The levels of mitochondrial cytochrome c were lower in cells treated with dasatinib + CA-4 than in cells treated with dasatinib or CA-4 as single agents (Fig. 3C) . Collectively, these results demonstrated that the dasatinib plus CA-4 combination therapy caused mitochondrial release of cytochrome c for activation of proteases leading to substrate cleavage.
Mcl-1 overexpression rescues cells from synergistic killing by the combination of dasatinib and CA-4.
We found that Mcl-1 expression was markedly downregulated in dasatinib plus CA-4 combination-treated cells compared with single agent alone, indicating that Mcl-1 might be involved in the synergistic effect of the combination treatment (Fig. 3B) . To further analyze whether Mcl-1 downregulation was required for dasatinib plus CA-4 combination treatment-induced apoptosis, we performed Mcl-1 overexpression experiments. We successfully increased the protein expression of Mcl-1 in HO-8910 cells by transfecting with pTOPO-Mcl-1 plasmid (Fig. 3D) . The decrease of pro-caspase-3 caused by dasatinib plus CA-4 was also increased due to the elevated levels of Mcl-1 in the cells (Fig. 3E) . Our observations indicate that the downregulation (Fig. 4B) .
The antitumor activity of dasatinib and CA-4 combination therapy against human HO-8910 xenografts.
To further characterize the anticancer efficacy of combination treatment, the in vivo activity of dasatinib and CA-4 was tested on an ovarian cancer HO-8910 xenograft model in nude mice. As shown in Fig. 5 and Table I , the i.g. administration of dasatinib at a dose of 5 mg/kg four times every week for 19 days produced slight antitumor effect in mean RTV compared with that of the control group (mean RTV, CA-4 vs. control: 9.3 vs. 12.7; P>0.05). However, with the dosage of 6 mg/kg four times every week for 19 days, CA-4 exerted a moderate tumor growth inhibitory effect (mean RTV, CA-4 vs. control: 8.7 vs. 12.7; P<0.05). As expected, dasatinib plus CA-4 caused marked tumor growth inhibition (T/C value, 48.8%), significantly greater than CA-4-(T/C value, 68.5%) or dasatinib treatment alone (T/C value, 73.2%). The RTV of the combination group was markedly decreased compared to that of the control group (P<0.01); notably, compared with the dasatinib or the CA-4 group, the combination group exerted significantly more potent antitumor activities against the HO-8910 xenograft in nude mice.
Discussion
Dasatinib, an orally active, small molecule targeting agent that inhibits multiple members of the SRC family and other tyrosine kinases, such as PDGFR, is initially approved for use in Ph+ acute lymphoblastic leukemia and is currently undergoing clinical trials in a variety of solid tumor types (26) . Dasatinib reduces angiogenesis and metastasis through inhibiting Src family kinases (27) . Inhibitors of angiogenesis interfere with new vessel formation and therefore have a preventative action, with little effect on the existing tumor blood vessels, and are likely to be of particular benefit in early-stage cancer therapy (28) . Vascular-disrupting agents target the established tumor blood vessels, resulting in tumor ischemia and necrosis (29) . CA-4 is the lead compound as a vasculardisrupting agent and is currently in Phase II/III clinical trials against a range of malignancies, in combination with conventional chemotherapeutic agents and radiotherapy (30, 31) . Furthermore, CA-4 displays minimal toxicity profile at low dose, indicating its potential as a candidate for drug combinations in the solid tumor therapy (32, 33) . Since both the initiation of new vessel formation and the integrity of the existing blood vessel network are critical to tumor growth and survival, various combinations involving an antiangiogenic agent and an antivascular agent could cause significantly more effective antitumor responses in various preclinical models (34) . Thus, combining dasatinib with CA-4 may be a logical way to potentially enhance response rates and prolong survival times for patients by targeting tumor blood vessels.
The results of the present report, for the first time, indicated that the synergistic anticancer effects in vitro and in vivo achieved by dasatinib plus CA-4 were observed in human cancer cells and a xenograft nude mice model. CI values and the significant decline of the survival curves in the combination group strongly demonstrated that dasatinib potentiated the CA-4-imposed cytotoxicity in 5 human solid tumor cell lines, including ovarian cancer (HO-8910), hepatocellular carcinoma (HepG2, SMMC-7721), non-small cell lung cancer (A549) and prostate cancer (PC-3). Furthermore, the strong synergistic effect was also validated on the HO-8910 xenograft nude mice model. As single agents, dasatinib and CA-4 merely displayed insignificant activities against the HO-8910 xenograft model, respectively; by contrast, the coadministration of dasatinib and CA-4 clearly arrested tumor growth by 51.2%. Moreover, the combination of dasatinib and CA-4 markedly improved the antitumor capacities in vivo without increasing toxicities, as indicated by the nearly constant body weights in the combination-treated group on day 19. As we reported, the combination of dasatinib and CA-4 might be an effective therapeutic strategy to achieve synergistic antitumor effects in patients with solid tumors.
Our data showed that synergism in vitro achieved by the combination of dasatinib and CA-4 was accompanied by enhanced apoptosis. Activation of caspase-3 leads to the cleavage of PARP, the presence of cleaved PARP is one of the most used diagnostic tools for the detection of apoptosis in several cell types (35) . From western blot analysis, marked increases in cleaved-PARP and caspase-3 were observed in HO-8910 cells following dasatinib and CA-4 combination treatment. IAPs also play an important role during the apoptotic process; XIAP is the best known member of this family, and correlates with resistance to chemotherapy (36) . Our data showed that the synergistic effect on apoptosis obtained with the dasatinib/CA-4 co-treatment was accompanied by a large decrease in antiapoptotic XIAP protein. Mitochondria play a key role in apoptotic cell death by releasing the effector proteins, including cytochrome c and Smac/DIABLO, from the mitochondrial intermembrane space (IMS) (37) . Our results showed that loss of mitochondrial membrane potential was significantly greater with dasatinib plus CA-4 than with either drug alone, suggesting that combination therapy might activate the mitochondrial-mediated apoptosis pathway in HO-8910 cells. In addition, we observed that the combination of dasatinib and CA-4 enhanced cytochrome c release from mitochondria into the cytosol in HO-8910 cells. IMS protein release can result from the mitochondrial outer membrane permeabilization (MOMP), which is thought to be regulated by proteins of the Bcl-2 family (38) . The Bcl-2 protein family includes proapoptotic members, such as Bax, Bad and Bcl-Xs, and antiapoptotic members, such as Bcl-2, Bcl-XL and Mcl-1. Antiapoptotic members act as repressors of apoptosis by blocking the release of cytochrome c, whereas proapoptotic members act as promoters (39) . The final action is dependent on the balance between Bcl-2 and Bax, and the increase of Bax/ Bcl-2 ratio can induce the release of cytochrome c (40) . Our results demonstrated a marked increase of the Bax/Bcl-2 ratio in HO-8910 cells treated with dasatinib plus CA-4, indicating that the regulation of Bcl-2 protein family expression plays an important role in combination-induced apoptosis. Mcl-1, primarily localized to the outer mitochondrial membrane, has been suggested to function as an antiapoptotic factor by suppressing cytochrome c release from mitochondria via heterodimerization with and neutralization of effector proapoptotic Bcl-2 family members. Mcl-1 expression was not altered in either the dasatinib or the CA-4 treatment group; however, dasatinib plus CA-4 treatment significantly downregulated the expression of Mcl-1 in HO-8910 cells, indicating that Mcl-1 might be involved in the synergistic effect of combination treatment. Moreover, elevated expression of Mcl-1 led to a reduced apoptosis induced by dasatinib plus CA-4, highlighting that downregulated Mcl-1 was necessary for the potentiating effect of dasatinib to CA-4-triggered apoptosis.
Among the different forms of complex DNA damage, double-strand breaks (DSBs) are considered to be among the most lethal forms of DNA damage, severely compromising genomic stability (41) . H2AX moved to the center of cellular responses to DNA damage after the discovery that it becomes locally phosphorylated on Ser139, to generate γ-H2AX, in the vicinity of DSBs (42) . Quantitation of γ-H2AX is one of the earliest events in the DNA damage signaling and repair (43, 44) . To maintain genomic stability following DNA damage, multicellular organisms activate checkpoints that induce cell cycle arrest or apoptosis (45) . A number of anticancer drugs exert their effect by causing DSBs and subsequent apoptosis induction, such as DNA replication inhibitors, crosslinking agents and topoisomerase inhibitors (46) . In our study, a clear increase in γ-H2AX expression was observed in the dasatinib + CA-4 group compared with the mono-treatment groups. Furthermore, in HO-8910 cells, the number of γ-H2AX-positive cells increased in the combination treatment group. These results indicated that dasatinib plus CA-4 might induce DSBs in HO-8910 cells, thereby activating apoptosis pathways, and finally resulting in the synergism of these two drugs.
In conclusion, we presented evidence showing enhanced therapeutic activity of dasatinib when combined with CA-4 in vitro and in vivo. The enhanced apoptosis induced by dasatinib plus CA-4 was accompanied by the larger extent of DNA damage, mitochondrial depolarization, caspase-3 activation and PARP cleavage in HO-8910 cells. Additional preclinical studies, such as antivascular efficacy, are required to systematically evaluate the applicability of this combination as a therapeutic strategy for cancer patients. As we reported, the combination of dasatinib and CA-4 might be an effective therapeutic strategy to achieve synergistic antitumor effects.
